Member Info for bewise

Looking foward to Jan 19 per operational rns update on 6th Nov :)

Completed patient enrollment in its Phase 2 clinical trial evaluating RPL554 as an add-on to dual bronchodilator therapy for COPD maintenance treatment. The Company confirmed that it expects top-line data in January 2019.

Not surprised by the big buy if correct, the sp is at rock bottom and a good entry level imo, a bit of catch up to be done on the this side of the pond!

Yes sentiment very low, the political turmoil is having quite an effect on share prices. Bargain basement prices with vrp imo, a bit of a steal at this level especially as we now how the sp can quickly rise here...you possibly might get large buys imo next week as investors smell an opportunity. Lets see what happens next week...

Good to see the two rns, steady ahead....in my speculative opinion far in excess of the present price, dont like to put a finger on it,the copd market is huge not to mention the cf aspect...:)

Imo value will out at P3 then to market...:)

Great news re CF from the RNS... :)

It takes a very long time for a treatment to come to market as we know and some of us are prepared for the long game(long haul) and some are not and others are locked in. If this gets through P3 and is successful then of course the sp will be different from today imo. Yes I would like to see a far far higher sp than presently but it is what it is at the mo but I am looking ahead to all test results next year & P3 through to the early 2020's :) This journey with vrp has defo been a rollercoaster....

Good publicity for 554 within the copd world and further.. :)

Nice one.....vrp a company with great propects in relation to 554 :)

LONDON, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that Jan-Anders Karlsson, CEO of Verona Pharma, will host an investment community conference call detailing the expanded dataset from RPL554 Phase 2b clinical trial in COPD to be presented in an oral presentation at the European Respiratory Society International Congress on Monday, September 17 at 8:30 a.m. CEST.

http://www.veronapharma.com/blog/verona-pharma-announces-publication-of-key-paper-on-rpl554-in-copd-in-the-european-respiratory-journal/

Excellant RNS, a respected journal :)

Really lol... :)

I see the Chairman purchased shares on Friday :)

Imo there is a bright future ahead for 554 as it continues to deliver and eventually i believe this will be reflected in the sp...its a long play circa...

A nice new research note from singers published :) :) :)

Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2018

http://www.veronapharma.com/news-and-media/

Great...moving forward towards P3 :)

GSKmepolizumab for the treatment of COPD patients on maximum inhaled therapy......could bode well for 554 :)

Nothing like a good bit of banter from fellow posters :) Value inflection points to come over the next 12 month, onwards and upwards..

A lot of inflection points over the next 12 months, please log on to the vep website which details the timetable of events....very happy and upbeat with my investment in vrp, imo sp value will come, i am playing the long game...the negative posters do amuse me with their musings but I invest based on facts and at this point 554 cleary works :)